초록 close

Objectives:Delirium is a disorder that needs active treatments since it is associated with poor outcomes such as comorbidity, longer hospital stay, higher mortality rate, higher rates of institutional care and dementia. This study was done to investigate the efficacy and safety of amisulpride, a atypical antipsychotic drug that is in possession of distinguishable pharmacodynamic profile characteristics from other widely used atypical antipsychotic drugs, but it has characteristics that are most similar to haloperidol which was the most commonly used antipsychotic drug treating patients with delirium in a safe manner. Methods:We recruited 19 delirium patients. Korean version of Delirium Rating Scale-Revised-98(K-DRS-R-98) and Korean version of Delirium Rating Scale(K-DRS) had been used to measure severity and improvement of delirium symptoms. Clinical Global Impression Severity Score(CGI-S) had been used to examine general medical conditions in the patients. The assessment on side effects began from day 2 for every visit to patients using Simpson-Angus Scale(SAS), Barnes Akathisia Rating Scale(BARS), Abnormal Involuntary Movement Scale(AIMS). Results:A total of 14 patients completed the study. They were administered with mean amisulpride dose 86.16 (SD=39.01) mg per day. The K-DRS scores were decreased from 21.57±4.72 before the treatment to 7.14±0.84 after the treatment(p<0.01). The K-DRS-R-98 scores also were significantly decreased from 25.07±6.40 before the treatment to 9.93±1.09 after the treatment(p<0.01). Among detailed K-DRS-R-98 scale items, the sleep item also showed a significant decrease(p<0.01). There was no patient who suffered serious side effects. In 35.7% of the patients, the mild rigidity and mild tremor of extrapyramidal symptoms occurred. Conclusion:Amisulpride is expected to be used effectively and safely in treating delirium patients